Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Atezolizumab + SBRT in HPV-unrelated HNSCC
NCT05053737Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Safety determined by Adverse Events at 24 months and Major Pathologic Response at 24 months. Started Nov 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05053737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053737.